1948 related articles for article (PubMed ID: 8137264)
21. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
22. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
23. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
24. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein.
Pink JJ; Jiang SY; Fritsch M; Jordan VC
Cancer Res; 1995 Jun; 55(12):2583-90. PubMed ID: 7780972
[TBL] [Abstract][Full Text] [Related]
25. Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Somaï S; Chaouat M; Jacob D; Perrot JY; Rostène W; Forgez P; Gompel A
Int J Cancer; 2003 Jul; 105(5):607-12. PubMed ID: 12740907
[TBL] [Abstract][Full Text] [Related]
26. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Sengupta K; Banerjee S; Saxena N; Banerjee SK
Int J Oncol; 2003 Mar; 22(3):609-14. PubMed ID: 12579315
[TBL] [Abstract][Full Text] [Related]
27. Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells.
Steinmetz R; Young PC; Caperell-Grant A; Gize EA; Madhukar BV; Ben-Jonathan N; Bigsby RM
Cancer Res; 1996 Dec; 56(23):5403-9. PubMed ID: 8968093
[TBL] [Abstract][Full Text] [Related]
28. The influence of antiestrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells.
Rajah TT; Dunn ST; Pento JT
Anticancer Res; 1996; 16(2):837-42. PubMed ID: 8687138
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
Gong Y; Ballejo G; Murphy LC; Murphy LJ
Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
[TBL] [Abstract][Full Text] [Related]
30. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
32. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
Parisot JP; Leeding KS; Hu XF; DeLuise M; Zalcberg JR; Bach LA
Breast Cancer Res Treat; 1999 Jun; 55(3):231-42. PubMed ID: 10517168
[TBL] [Abstract][Full Text] [Related]
33. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
34. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.
Chalbos D; Philips A; Galtier F; Rochefort H
Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199
[TBL] [Abstract][Full Text] [Related]
35. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Brünner N; Frandsen TL; Holst-Hansen C; Bei M; Thompson EW; Wakeling AE; Lippman ME; Clarke R
Cancer Res; 1993 Jul; 53(14):3229-32. PubMed ID: 8324732
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
37. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Müller V; Jensen EV; Knabbe C
Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
[TBL] [Abstract][Full Text] [Related]
38. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
39. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
40. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells.
Coradini D; Biffi A; Cappelletti V; Di Fronzo G
Anticancer Res; 1994; 14(3A):1059-64. PubMed ID: 8074450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
